Australian health technology leader Analise.ai launches next-generation CT Brain AI solution for clinical use

October 18, 2022 — Global leader in AI in medical imaging annalise.aian has announced that its latest product release, an AI-enabled SaMD (software as a medical device) decision support solution for CT brain studies without contrast, is now clinically available in Australia, New Zealand and the UK.

Annalize Enterprise CTB (Annalize CTB) is the most clinically comprehensive decision support AI solution available on the market. Its innovative algorithm can identify 130 imaging findings, including a wide range of conditions that require urgent interventions. Annalize CTB is designed to be an assistive clinical tool, providing radiologists with a “second pair of eyes” to help them improve diagnostic accuracy and patient health outcomes.

Dr. Rick Abramson, Medical Director of annalise.ai, said, “Annalise Enterprise CTB represents a leap forward in the evolution of AI technology for neuroimaging. While most other brain CT AI products can only recognize a small handful of conditions, Annalize CTB helps the radiologist with 130 imaging results – meaning more support for the radiologist and more impact important in patient care. During our controlled product launch, we have already seen countless examples of critical pathologies that could have been missed but were successfully identified by Annalize CTB.

Annalize CTB’s support could have a particularly big impact on overworked radiology residents who report working hours at teaching hospitals and in areas facing difficult radiologist capacity constraints.

In addition to aiding in the detection of imaging findings, Annalize CTB is expected to streamline patient care workflows. By analyzing non-contrast cranial CT scans as they are acquired, the solution can provide a notification signal for urgent cases, helping radiologists triage high-priority cases requiring rapid action.

Annalizes Enterprise CTB:

  1. Is the first commercially available medical imaging AI solution to detect over 100 findings on non-contrast brain scans
  2. Trained on one of the world’s largest label datasets of non-contrast CT brain studies, hand-labeled by 143 radiologists, generating over 240,000,000 CTB labels
  3. Was designed for clinicians, with features such as a confidence bar for each result and a user interface that enables seamless integration into a radiologist’s workflow
  4. Automatically highlights suspected location of findings on multiplanar reformatted images with pathology-appropriate window and level settings
  5. Demonstrated improvements in reporting accuracy and changes to patient management in a recent 6-week pilot study with 11 radiologists using the solution as an assistive tool.

The release of Annalize CTB builds on the successful launch of Annalize Enterprise CXR, the world’s most comprehensive decision support AI solution for chest x-ray and, together with Annalize Enterprise CXR, is now part of the Annalize Enterprise suite of products. Annalize Enterprise is an enterprise IT solution offering healthcare providers access to annalise.ai’s comprehensive AI modules intended to assist clinicians in the interpretation of medical imaging studies. Annalize Enterprise is now used by many radiologists at a large number of sites in the UK and Australia. The new Annalize CTB module is expected to help annalise.ai continue its mission of helping one million patients every day.

For more information: www.annalise.ai

Comments are closed.